Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer's disease

K. Veverová, A. Katonová, H. Horáková, J. Laczó, F. Angelucci, J. Hort, S. Lautrup, EF. Fang, M. Vyhnálek

. 2025 ; 13 (1) : 37. [pub] 20250220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009842

Grantová podpora
TO01000215 KAPPA programme
LX22NPO5107 National Institute for Neurological Research
6980382 Institutional Support of Excellence

Maintaining cellular homeostasis by removing damaged and senescent mitochondria, a process termed mitophagy, is crucial in preventing Alzheimer's disease (AD) and represents a promising therapeutic target. Our previous research revealed altered mitophagy biomarkers, such as increased CSF and serum PINK1 and serum BNIP3L and decreased serum TFEB levels, indicating impaired autophagy-lysosomal degradation in the AD continuum. However, the role of autophagy/mitophagy in frontotemporal lobar degeneration (FTLD) remains unclear. This study investigated the biomarkers of autophagy/mitophagy and lysosomal biogenesis (PINK1, ULK1, BNIP3L, and TFEB) in biofluids (CSF and serum) from 308 biomarker-defined individuals across the FTLD continuum (FTLD-dementia, n = 29; FTLD-MCI, n = 33) and compared them with those across the AD continuum (MCI-AD, n = 100; AD-dementia, n = 100) and cognitively unimpaired (CU) controls (n = 46) recruited from Czech Brain Aging Study. Additionally, we compared the mitophagy biomarkers across different FTLD clinical subtypes (frontal, semantic and nonfluent variant) with CU, and explored the association between mitophagy biomarkers and clinical phenotypes of FTLD (biomarkers of tau, biomarkers of neurodegeneration, cognition and ATN profile).Our findings indicated a significantly lower CSF PINK1 and ULK1 levels in FTLD compared to AD, with FTLD dementia showing particularly low CSF PINK1 levels compared to AD-dementia. Conversely, CSF ULK1 levels were higher in FTLD-MCI compared to AD-dementia. Serum analyses revealed lower PINK1 and higher TFEB levels in FTLD dementia compared to AD dementia. This study provides compelling evidence of distinct alterations in autophagy/mitophagy biomarkers between FTLD and AD, indicating that these neurodegenerative diseases may affect the cellular waste disposal system through different pathways. This is the first study to explore mitophagy biomarkers in human CSF and serum in FTLD, opening avenues for further research and potential clinical applications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009842
003      
CZ-PrNML
005      
20250429135538.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40478-025-01954-9 $2 doi
035    __
$a (PubMed)39972393
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Veverová, Kateřina $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic $1 https://orcid.org/0000000258451854
245    10
$a Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer's disease / $c K. Veverová, A. Katonová, H. Horáková, J. Laczó, F. Angelucci, J. Hort, S. Lautrup, EF. Fang, M. Vyhnálek
520    9_
$a Maintaining cellular homeostasis by removing damaged and senescent mitochondria, a process termed mitophagy, is crucial in preventing Alzheimer's disease (AD) and represents a promising therapeutic target. Our previous research revealed altered mitophagy biomarkers, such as increased CSF and serum PINK1 and serum BNIP3L and decreased serum TFEB levels, indicating impaired autophagy-lysosomal degradation in the AD continuum. However, the role of autophagy/mitophagy in frontotemporal lobar degeneration (FTLD) remains unclear. This study investigated the biomarkers of autophagy/mitophagy and lysosomal biogenesis (PINK1, ULK1, BNIP3L, and TFEB) in biofluids (CSF and serum) from 308 biomarker-defined individuals across the FTLD continuum (FTLD-dementia, n = 29; FTLD-MCI, n = 33) and compared them with those across the AD continuum (MCI-AD, n = 100; AD-dementia, n = 100) and cognitively unimpaired (CU) controls (n = 46) recruited from Czech Brain Aging Study. Additionally, we compared the mitophagy biomarkers across different FTLD clinical subtypes (frontal, semantic and nonfluent variant) with CU, and explored the association between mitophagy biomarkers and clinical phenotypes of FTLD (biomarkers of tau, biomarkers of neurodegeneration, cognition and ATN profile).Our findings indicated a significantly lower CSF PINK1 and ULK1 levels in FTLD compared to AD, with FTLD dementia showing particularly low CSF PINK1 levels compared to AD-dementia. Conversely, CSF ULK1 levels were higher in FTLD-MCI compared to AD-dementia. Serum analyses revealed lower PINK1 and higher TFEB levels in FTLD dementia compared to AD dementia. This study provides compelling evidence of distinct alterations in autophagy/mitophagy biomarkers between FTLD and AD, indicating that these neurodegenerative diseases may affect the cellular waste disposal system through different pathways. This is the first study to explore mitophagy biomarkers in human CSF and serum in FTLD, opening avenues for further research and potential clinical applications.
650    _2
$a lidé $7 D006801
650    12
$a Alzheimerova nemoc $x krev $x patologie $x mozkomíšní mok $7 D000544
650    12
$a frontotemporální lobární degenerace $x patologie $x mozkomíšní mok $x krev $7 D057174
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    12
$a biologické markery $x mozkomíšní mok $x krev $7 D015415
650    12
$a mitofagie $7 D063306
650    12
$a autofagie $x fyziologie $7 D001343
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a proteinkinasy $x metabolismus $x krev $7 D011494
650    _2
$a homolog Atg1 $x metabolismus $7 D000071189
650    _2
$a intracelulární signální peptidy a proteiny $7 D047908
655    _2
$a časopisecké články $7 D016428
700    1_
$a Katonová, Alžběta $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
700    1_
$a Horáková, Hana $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
700    1_
$a Laczó, Jan $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
700    1_
$a Angelucci, Francesco $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
700    1_
$a Lautrup, Sofie $u Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, 1478, Norway $u The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway
700    1_
$a Fang, Evandro Fei $u Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, 1478, Norway. e.f.fang@medisin.uio.no $u The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway. e.f.fang@medisin.uio.no
700    1_
$a Vyhnálek, Martin $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic. martin.vyhnalek@lfmotol.cuni.cz $1 https://orcid.org/0000000259764932 $7 xx0070891
773    0_
$w MED00209779 $t Acta neuropathologica communications $x 2051-5960 $g Roč. 13, č. 1 (2025), s. 37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39972393 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135533 $b ABA008
999    __
$a ok $b bmc $g 2311307 $s 1246923
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 13 $c 1 $d 37 $e 20250220 $i 2051-5960 $m Acta neuropathologica communications $n Acta Neuropathol Commun $x MED00209779
GRA    __
$a TO01000215 $p KAPPA programme
GRA    __
$a LX22NPO5107 $p National Institute for Neurological Research
GRA    __
$a 6980382 $p Institutional Support of Excellence
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...